Trials / Recruiting
RecruitingNCT06460038
Tenapanor in Synucleinopathy-Related Constipation
Efficacy and Safety of Tenapanor in Synucleinopathy-Related Constipation
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Cedar Valley Digestive Health Center · Academic / Other
- Sex
- All
- Age
- 50 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation
Detailed description
Randomized, double-blind, placebo controlled trial of tenapanor vs. placebo for treating synucleinopathy-associated constipation in Parkinson\'s disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenapanor | Inhibitor of NHE3 |
| DRUG | Placebo | Placebo drug |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2026-12-01
- Completion
- 2027-03-01
- First posted
- 2024-06-14
- Last updated
- 2025-02-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06460038. Inclusion in this directory is not an endorsement.